Cycrimine

Cycrimine is an orally active muscarinic cholinergic receptor (mAChR) M1 antagonist, reduces the acetylcholine levels in parkinson model. Cycrimine shows antispasmodic activity, can be used in studies of behavioral and mental disorder[1][2][3][4].

Product Specifications

CAS Number

[77-39-4]

UNSPSC

12352005

Hazard Statement

H315-H319-H320

Target

MAChR

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/cycrimine.html

Purity

99.85

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

OC(C1CCCC1)(C2=CC=CC=C2)CCN3CCCCC3

Molecular Formula

C19H29NO

Molecular Weight

287.44

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]David T. CHAU. Methods of treating behaviorial and/or mental disorders. WO2014176460A1.|[2]Marzoughi S, et al. Tardive neurotoxicity of anticholinergic drugs: A review. J Neurochem. 2021 Sep;158 (6) :1334-1344. |[3]Tacke, et al. Syntheses and pharmacological characterization of achiral and chiral enantiopure C/Si/Ge-analogous derivatives of the muscarinic antagonist cycrimine: a study on C/Si/Ge bioisosterism. Journal of organometallic chemistry 640.1-2 (2001) : 140-165. |[4]MAGEE KR, et al. Antispasmodic compound 08958 in treatment of paralysis agitans. J Am Med Assoc. 1953 Oct 24;153 (8) :715-8.